Steris | STE - Cash And Equivalent


Steris reported $482.3M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
3M USD 4.84B 1.88B Sep/2026
Accuray USD 41.29M 22.05M Dec/2025
Baxter International USD 1.98B 175M Sep/2026
Becton, Dickinson and Co. USD 725M 17M Sep/2026
Boston Scientific USD 609M 70M Sep/2026
CONMED USD 37.33M 2.3M Jun/2026
Cooper Companies USD 138.8M 13.9M Mar/2026
Dexcom USD 961.4M 143.6M Sep/2026
Ecolab USD 722.3M 4.41B Sep/2026
Edwards Lifesciences USD 3.11B 210.8M Sep/2026
Fortive USD 377.3M 3.1M Sep/2026
Getinge SEK 2.05B 909M Jun/2026
Globus Medical USD 441.27M 66.47M Sep/2026
Haemonetics USD 260.71M 37.33M Sep/2026
Idexx Laboratories USD 197.54M 603K Sep/2026
Inogen USD 106.48M 2.79M Sep/2025
Insulet USD 584.4M 49.5M Sep/2026
Integra LifeSciences USD 252.26M 37.85M Sep/2026
Intuitive Surgical USD 6.8B 1.83B Sep/2026
J&J USD 16.91B 3.51B Sep/2026
Olympus JPY 157.74B 10.5B Sep/2026
Orthofix International USD 86.32M 17.49M Sep/2026
Owens Minor USD 26.61M 18.96M Sep/2026
ResMed USD 1.01B 458.49M Sep/2026
Steris USD 482.3M 42.7M Jun/2026
Stryker USD 3.27B 120M Sep/2026
Tandem Diabetes Care USD 72.84M 10.02M Sep/2026
Teleflex USD 430.46M 130.31M Sep/2026
Thermo Fisher Scientific USD 5.46B 1.4B Sep/2026
Zimmer Biomet Holdings USD 399.9M 10.1M Sep/2026